peripheral arterial disease
Conditions
Interventions
Aspirin 81-100mg/day
Aspirin 81-100mg/day + cilostazol 200mg/day
Sponsors
Kokura Memorial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)PAD patients with intermittent claudication who had a de novo femoropopliteal disease without an inflow lesion (aortoiliac or common femoral lesion), with an outflow artery (below the knee arteries) with more than one vessel run-off, and with symptoms that were not improved by pharmacotherapy or exercise therapy 2) ankle-brachial index (ABI) of ≤ 0.9 3) a percentage stenosis diameter of ≥ 50% by visual estimate on angiography
Exclusion criteria
Exclusion criteria: previous lower extremity bypass surgery, previous EVT in the femoropopliteal artery, acute onset limb ischemia, or severe lower extremity ischemic symptoms classified into Rutherford Category 4, 5 or 6, known bleeding diathesis, hepatic dysfunction, active gastrointestinal bleeding or peptic ulcer disease, intolerance to cilostazol, aspirin or ticlopidine, pregnant women and women of child-bearing potential, and major life-threatening illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| target vessel revascularization | — |
Secondary
| Measure | Time frame |
|---|---|
| major adverse cardiovascular event, restenosis rate | — |
Countries
Japan
Outcome results
None listed